Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.13 -0.21 (-1.21%)

Delayed Quote Updated: 12:05 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

February 21, 2024

From Bausch + Lomb Corporation

Via Business Wire

Wall Street Waits With Bated Breath For Nvidia Earnings After Tech Selloff, Fed Minutes Eyed: Analyst Flags This As Biggest Risk For Market ↗

February 21, 2024

The market will broaden the sustenance of its rally when interest-rate cuts begin to be priced in and investors begin to think about the roadmap, an analyst said.

Via Benzinga

Topics Economy

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

Bausch & Lomb Earnings Preview ↗

February 20, 2024

Via Benzinga

The Latest Analyst Ratings for Bausch & Lomb ↗

December 04, 2023

Via Benzinga

Bausch & Lomb Earnings Preview ↗

October 31, 2023

Via Benzinga

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

6 Analysts Have This to Say About Bausch & Lomb ↗

October 03, 2023

Via Benzinga

Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month ↗

February 09, 2024

"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins...

Via Benzinga

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21

February 05, 2024

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

January 08, 2024

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

November 15, 2023

From Bausch + Lomb Corporation

Via Business Wire

Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News' ↗

November 01, 2023

U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings.

Via Benzinga

Topics Economy Stocks

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance

November 01, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting

October 26, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1

October 16, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

October 04, 2023

From Bausch + Lomb

Via Business Wire

Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift ↗

October 03, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy...

Via Benzinga

Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)

September 29, 2023

Via ACCESSWIRE

Bausch + Lomb Completes Acquisition of XIIDRA®

September 29, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States

September 26, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners

September 20, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Pricing of Senior Secured Notes Offering

September 14, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States

September 12, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)

September 11, 2023

Via ACCESSWIRE

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

September 11, 2023

From Bausch + Lomb Corporation

Via Business Wire

Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

September 08, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®

September 06, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting

September 06, 2023

From Bausch + Lomb Corporation

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.